RT Journal Article
SR Electronic
T1 Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.10.22271799
DO 10.1101/2022.03.10.22271799
A1 Sowalsky, Adam G.
A1 Figueiredo, Ines
A1 Lis, Rosina T.
A1 Coleman, Ilsa
A1 Gurel, Bora
A1 Bogdan, Denisa
A1 Yuan, Wei
A1 Russo, Joshua W.
A1 Bright, John R.
A1 Whitlock, Nichelle C.
A1 Trostel, Shana Y.
A1 Ku, Anson T.
A1 Patel, Radhika A.
A1 True, Lawrence D.
A1 Welti, Jonathan
A1 Jimenez-Vacas, Juan M.
A1 Rodrigues, Daniel Nava
A1 Riisnaes, Ruth
A1 Neeb, Antje
A1 Sprenger, Cynthia T.
A1 Swain, Amanda
A1 Wilkinson, Scott
A1 Karzai, Fatima
A1 Dahut, William L.
A1 Balk, Steven P.
A1 Corey, Eva
A1 Nelson, Peter S.
A1 Haffner, Michael C.
A1 Plymate, Stephen R.
A1 de Bono, Johann S.
A1 Sharp, Adam
YR 2022
UL http://medrxiv.org/content/early/2022/03/12/2022.03.10.22271799.abstract
AB Background Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown clinical utility as a predictive biomarker of AR-targeted therapy resistance in castration-resistant prostate cancer (CRPC), but its importance as predictive biomarker in CSPC remains understudied.Methods We explored multiple approaches to quantify AR-V7 mRNA and protein in prostate cancer cell lines and patient-derived xenograft (PDX) models, in both publicly available and independent institutional clinical cohorts, to identify reliable approaches for detecting AR-V7 mRNA and protein, and its association with clinical outcome.Results In publicly available benign prostate, CSPC and CRPC cohorts, AR-V7 mRNA was much less abundant when detected using reads across splice boundaries than when considering isoform-specific exonic reads. The RM7 AR-V7 antibody had increased sensitivity and specificity for AR-V7 protein detection by immunohistochemistry (IHC) in CRPC cohorts and identified AR-V7 protein reactivity very rarely in CSPC cohorts, when compared to the EPR15656 AR-V7 antibody. Using multiple CRPC PDX models, we demonstrated that AR-V7 expression was exquisitely sensitive to hormonal manipulation. In CSPC cohorts, AR-V7 protein quantification by either assay did not associate with time to development of castration-resistance or overall survival, and intense neoadjuvant androgen-deprivation therapy did not lead to significant detectable AR-V7 mRNA or staining following treatment, and neither pre- nor post-treatment AR-V7 levels associated with the volume of residual disease after therapy.Conclusion This study demonstrates that further analytical validation and clinical qualification is required before AR-V7 can be considered for clinical use in CSPC as a predictive biomarker.Competing Interest StatementR.T.L. performs consulting in an advisory role for Janssen Pharmaceuticals. E.C. has received research funding under institutional SRA from Janssen Research and Development, Bayer Pharmaceuticals, KronosBio, Forma Pharmaceutics, Foghorn, Gilead, Sanofi, AbbVie, MacroGenics, and GSK. P.S.N. has served as a paid advisor to Janssen, Bristol Myers Squibb, Venable/Fitzpatrick and received research funding from Janssen for work unrelated to the present study. S.R.P. has received research support from IMClone, Janssen and ESSA. He has received travel support and honoraria from Janssen and ImClone. He is president of ProsTech Inc. J.S.d.B. has served on advisory boards and received fees from many companies, including Amgen, Astra Zeneca, Astellas, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi, Eisai, Genentech/Roche, Genmab, GSK, Harpoon, ImCheck Therapeutics, Janssen, Merck Serono, Merck Sharp & Dohme, Menarini/Silicon Biosystems, Orion, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, and Vertex Pharmaceuticals. He is an employee of the ICR, which has received funding or other support for his research work from AstraZeneca, Astellas, Bayer, Cellcentric, Daiichi, Genentech, Genmab, GSK, Janssen, Merck Serono, MSD, Menarini/Silicon Biosystems, Orion, Sanofi Aventis, Sierra Oncology, Taiho, Pfizer, and Vertex, and which has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers, and PI3K/AKT pathway inhibitors (no personal income). J.S.d.B. was named as an inventor, with no financial interest, for patent 8,822,438, submitted by Janssen, that covers the use of abiraterone acetate with corticosteroids. J.S.d.B. has been the CI/PI of many industry-sponsored clinical trials. A.Sharp is an employee of the ICR, which has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers, and PI3K/AKT pathway inhibitors (no personal income). A. Sharp has received travel support from Sanofi and Roche-Genentech, and speaker honoraria from Astellas Pharma. He has served as an advisor to DE Research. A. Sharp has been the CI/PI of industry-sponsored clinical trials. The remaining authors declare no conflicts of interest.Funding StatementThis work was supported by Prostate Cancer UK (Travelling Prize Fellowship to J.M.J.V.; Research Funding to J.S.dB.), the Prostate Cancer Foundation (Young Investigator Awards to S.W., A.T.K., J.W.R., F.K., and A.Sharp; Challenge Awards to S.P.B., P.S.N., J.S.dB., A.Sharp), the Intramural Research Program of the NIH, National Cancer Institute, the Movember Foundation through the London Movember Centre of Excellence (CEO13 2-002 to J.S.dB.), the Congressionally Directed Medical Research Program Prostate Cancer Research Program (Early Investigator Research Award to J.W.R., Translational Science Award to S.R.P, and Transformative Impact Award to L.D.T), the Wellcome Trust (Clinical Research Career Development Fellowship to A.Sharp), the NIHR Biomedical Research Centre, Cancer Research UK (Centre Programme and Experimental Cancer Medicine Centre grants to J.S.dB.), the UK Department of Health, Biomedical Research Centre funding to the Royal Marsden, the Doris Duke Charitable Foundation (grant to M.C.H.), the V Foundation (to M.C.H.), the NIH (P50 CA090381 to S.P.B. and P.S.N; P50 CA090381 to S.P.B and C.T.S.; P50 CA097186 and R01 CA234715 to P.S.N.), the Veterans Affairs Research and Development Service (VA BLRD 2101BX003324 to S.R.P.), and the Lopker Family Foundation (to S.R.P.). Portions of this work utilized the computational resources of the NIH HPC Biowulf cluster. The establishment and characterization of the LuCaP patient-derived xenograft models was supported by the PNW Prostate Cancer SPORE P50CA097186, P01CA163227 and IPCR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics review committee of the Royal Marsden Hospital gave approval for this work with the Institute for Cancer Research cohort. The IRB of the University of Washington gave approval for this work with the University of Washington cohort. The IRBs of the Beth Israel Deaconess Medical Center and the Dana-Farber Harvard Cancer Center gave approval for this work with the localized prostate cancer National Cancer Institute cohort. The IRB of the National Institutes of Health gave approval for this work with the clinical trial National Cancer Institute cohort.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available from dbGaP and GEO. https://www.ncbi.nlm.nih.gov/gap/ https://www.ncbi.nlm.nih.gov/geo/